<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03091348</url>
  </required_header>
  <id_info>
    <org_study_id>MHB023</org_study_id>
    <nct_id>NCT03091348</nct_id>
  </id_info>
  <brief_title>Subcutaneous vs. Intramuscular Testosterone</brief_title>
  <official_title>Subcutaneous Testosterone Therapy in Men Compared to Intramuscular Testosterone Therapy in Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Men's Health Boston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Men's Health Boston</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this randomized, cross‐over study 20 subjects who are undergoing testosterone (T) therapy
      for the treatment of T deficiency will receive both subcutaneous testosterone therapy and
      intramuscular testosterone therapy. One group will receive a SQ injection followed by an IM
      injection and one group will receive an IM injection followed by a SQ injection. The primary
      objective of this study is to measure testosterone concentration in men after these two
      treatment routes and determine if there are any significant differences due to modes of
      administration. Endpoints will include total serum testosterone and calculated free
      testosterone. A questionnaire will also be administered to assess overall patient experience
      with each route of administration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects planning to initiate testosterone treatment via injection at MHB will be consented
      into the study. Upon enrollment in the study, the randomization will be completed for each
      subject.

      Blood collection will occur before each injection. Subjects will rate pain on the Likert
      scale following each injection. After treatment with the first mode of T administration (SQ
      or IM depending on randomization), subjects will come in for blood draws 3 days and 7 days
      following the injection. Two weeks after the initial injection, subjects will come in for
      treatment with the second mode of T administration (SQ or IM depending on randomization).
      Subjects will come in for blood draws 3 days and 7 days following the second injection. Two
      weeks after the second injection, subjects will complete an end of study assessment with an
      Investigator and will complete a survey assessing their satisfaction with treatment. Subjects
      will likely continue testosterone therapy at Men's Health Boston after completion of the
      study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 29, 2017</start_date>
  <completion_date type="Actual">January 2, 2018</completion_date>
  <primary_completion_date type="Actual">November 21, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Levels of Serum Total Testosterone Concentration</measure>
    <time_frame>&quot;Visit 2, Visit 3, Visit 4, Visit 5, Visit 6 and Visit 7&quot;</time_frame>
    <description>Blood samples measured by Beckman assays and equipment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Levels of Serum Calculated Free T Concentration</measure>
    <time_frame>&quot;Last visit ( Visit 7)&quot;</time_frame>
    <description>Blood samples measured by Beckman assays and equipment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Levels of Serum Estradiol</measure>
    <time_frame>&quot;Visit 2, Visit 3, Visit 4, Visit 5, Visit 6 and Visit 7&quot;</time_frame>
    <description>Blood samples measured by Beckman assays and equipment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Levels of Serum LH</measure>
    <time_frame>&quot;Visit 2, Visit 3, Visit 4, Visit 5, Visit 6 and Visit 7&quot;</time_frame>
    <description>Blood samples measured by Beckman assays and equipment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Levels of Serum FSH</measure>
    <time_frame>&quot;Visit 2, Visit 3, Visit 4, Visit 5, Visit 6 and Visit 7&quot;</time_frame>
    <description>Blood samples measured by Beckman assays and equipment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Levels of Serum SHBG</measure>
    <time_frame>&quot;Visit 2, Visit 3, Visit 4, Visit 5, Visit 6 and Visit 7&quot;</time_frame>
    <description>Blood samples measured by Beckman assays and equipment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Level of Serum PSA</measure>
    <time_frame>&quot;Last visit (Visit 7)&quot;</time_frame>
    <description>Blood samples measured by Beckman assays and equipment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Levels of Whole Blood Hematocrit</measure>
    <time_frame>&quot;Last visit (Visit 7)&quot;</time_frame>
    <description>Blood samples measured by Quest assays and equipment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Low Testosterone Questionnaire Responses</measure>
    <time_frame>after last vist #7</time_frame>
    <description>Answers recorded at baseline, 2 weeks, up to 4 weeks. Scale is 1-5 (strongly disagree to strongly agree) Lower scores are better</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in International Prostate Symptom Scores</measure>
    <time_frame>after last vist #7</time_frame>
    <description>Answers recorded at baseline, 2 weeks, up to 4 weeks.
Scale 0-35, from Mild to Severe Lower score is better</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Testosterone Deficiency</condition>
  <condition>Hypogonadism, Male</condition>
  <arm_group>
    <arm_group_label>SQ - IM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous testosterone injection followed by intramuscular testosterone injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IM - SQ</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intramuscular testosterone injection followed by subcutaneous testosterone injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone</intervention_name>
    <description>Testosterone cypionate injection</description>
    <arm_group_label>IM - SQ</arm_group_label>
    <arm_group_label>SQ - IM</arm_group_label>
    <other_name>Testosterone cypionate</other_name>
    <other_name>Testosterone injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability to read, write, and understand English

          -  Age greater than or equal to 18

          -  Diagnosed with testosterone deficiency

          -  Pre‐enrollment testosterone concentration of less than 350 ng/dL

          -  Planning to initiate testosterone treatment at MHB

          -  Willing to be followed at MHB for at least one month

          -  Willing to provide informed consent for this study

        Exclusion Criteria:

          -  Previous exposure to exogenous T, clomiphene citrate, or other Selective Estrogen
             Receptor Modulators, unless off therapy for at least 12 weeks

          -  American Urological Association Prostate Symptom score of 15 or greater or significant
             prostatic symptoms

          -  History of carcinoma, tumors or induration of the prostate or the male mammary gland,
             including suspicion thereof

          -  Pre‐enrollment serum PSA more than 4 ng/ml

          -  Serious psychiatric disease or uncontrolled medical illness, as suspected from the
             history or clinical examination

          -  Used any sex hormones or steroidal anabolic drug supplements within 28 days before
             pre‐enrollment testosterone collection or at any time throughout the study

          -  Incapable of giving informed consent or complying with the protocol
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abraham Morgentaler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Men's Health Boston, Harvard Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Men's Health Boston</name>
      <address>
        <city>Chestnut Hill</city>
        <state>Massachusetts</state>
        <zip>02467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>March 16, 2017</study_first_submitted>
  <study_first_submitted_qc>March 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2017</study_first_posted>
  <results_first_submitted>January 14, 2019</results_first_submitted>
  <results_first_submitted_qc>September 4, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 25, 2019</results_first_posted>
  <last_update_submitted>September 27, 2019</last_update_submitted>
  <last_update_submitted_qc>September 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Men's Health Boston</investigator_affiliation>
    <investigator_full_name>Dr. Abraham Morgentaler</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypogonadism</mesh_term>
    <mesh_term>Eunuchism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methyltestosterone</mesh_term>
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 23, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/48/NCT03091348/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>SQ - IM</title>
          <description>Subcutaneous testosterone injection followed by intramuscular testosterone injection
Testosterone: Testosterone cypionate injection</description>
        </group>
        <group group_id="P2">
          <title>IM - SQ</title>
          <description>Intramuscular testosterone injection followed by subcutaneous testosterone injection
Testosterone: Testosterone cypionate injection</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Participants analyzed is 0 and 1 due to loss to follow up</population>
      <group_list>
        <group group_id="B1">
          <title>SQ-IM</title>
          <description>Subcutaneous testosterone injection followed by intramuscular testosterone injection
Testosterone: Testosterone cypionate injection</description>
        </group>
        <group group_id="B2">
          <title>IM-SQ</title>
          <description>Intramuscular testosterone injection followed by subcutaneous testosterone injection
Testosterone: Testosterone cypionate injection</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
            <count group_id="B2" value="1"/>
            <count group_id="B3" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>loss to follow up</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="44" spread="0"/>
                    <measurement group_id="B3" value="44" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>loss to follow up caused only 1 subject to be analyzed</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <population>loss to follow up</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Estradiol (E2)</title>
          <population>loss to follow up</population>
          <units>pg/ml</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="24.5"/>
                    <measurement group_id="B3" value="24.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Human Follicle Stimulating Hormone (hFSH)</title>
          <population>loss to follow up</population>
          <units>miu/ml</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="3.5"/>
                    <measurement group_id="B3" value="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hemophagocytic lymphohistiocytosis(hLH)</title>
          <population>loss to follow up</population>
          <units>miu/ml</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex hormone binding globulin(SHBG)</title>
          <population>loss to follow up</population>
          <units>nmol/l</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="27.3"/>
                    <measurement group_id="B3" value="27.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Testosterone</title>
          <population>loss to follow up</population>
          <units>ng/dl</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="317.1"/>
                    <measurement group_id="B3" value="317.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Levels of Serum Total Testosterone Concentration</title>
        <description>Blood samples measured by Beckman assays and equipment.</description>
        <time_frame>&quot;Visit 2, Visit 3, Visit 4, Visit 5, Visit 6 and Visit 7&quot;</time_frame>
        <population>loss to follow up</population>
        <group_list>
          <group group_id="O1">
            <title>&quot;SQ&quot;</title>
            <description>Subcutaneous testosterone injection Testosterone: Testosterone cypionate injection</description>
          </group>
          <group group_id="O2">
            <title>&quot;IM&quot;</title>
            <description>Intramuscular testosterone injection Testosterone: Testosterone cypionate injection</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Levels of Serum Total Testosterone Concentration</title>
          <description>Blood samples measured by Beckman assays and equipment.</description>
          <population>loss to follow up</population>
          <units>ng/dl</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>visit 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">design of the study is cross over, with only 1 subjects</measurement>
                    <measurement group_id="O2" value="1043.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>visit 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">design of the study is cross over, with only 1 subjects</measurement>
                    <measurement group_id="O2" value="785.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>visit 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="203.5"/>
                    <measurement group_id="O2" value="NA">design of the study is cross over, with only 1 subjects</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>vist 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1367.9"/>
                    <measurement group_id="O2" value="NA">design of the study is cross over, with only 1 subjects</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>visit 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="980.8"/>
                    <measurement group_id="O2" value="NA">design of the study is cross over, with only 1 subjects</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>visit 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144.7"/>
                    <measurement group_id="O2" value="NA">design of the study is cross over, with only 1 subjects</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Levels of Serum Calculated Free T Concentration</title>
        <description>Blood samples measured by Beckman assays and equipment.</description>
        <time_frame>&quot;Last visit ( Visit 7)&quot;</time_frame>
        <population>loss to follow up</population>
        <group_list>
          <group group_id="O1">
            <title>&quot;SQ&quot;</title>
            <description>Subcutaneous testosterone injection Testosterone: Testosterone cypionate injection</description>
          </group>
          <group group_id="O2">
            <title>&quot;IM&quot;</title>
            <description>Intramuscular testosterone injection Testosterone: Testosterone cypionate injection</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Levels of Serum Calculated Free T Concentration</title>
          <description>Blood samples measured by Beckman assays and equipment.</description>
          <population>loss to follow up</population>
          <units>ng/dL</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.84"/>
                    <measurement group_id="O2" value="14.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Levels of Serum Estradiol</title>
        <description>Blood samples measured by Beckman assays and equipment.</description>
        <time_frame>&quot;Visit 2, Visit 3, Visit 4, Visit 5, Visit 6 and Visit 7&quot;</time_frame>
        <population>loss to follow up</population>
        <group_list>
          <group group_id="O1">
            <title>&quot;SQ&quot;</title>
            <description>Subcutaneous testosterone injection Testosterone: Testosterone cypionate injection</description>
          </group>
          <group group_id="O2">
            <title>&quot;IM&quot;</title>
            <description>Intramuscular testosterone injection Testosterone: Testosterone cypionate injection</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Levels of Serum Estradiol</title>
          <description>Blood samples measured by Beckman assays and equipment.</description>
          <population>loss to follow up</population>
          <units>pg/mL</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>visit 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">cross over study design</measurement>
                    <measurement group_id="O2" value="70.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>visit 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">cross over study design</measurement>
                    <measurement group_id="O2" value="52.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>visit 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.06"/>
                    <measurement group_id="O2" value="NA">cross over study design</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>visit 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.12"/>
                    <measurement group_id="O2" value="NA">cross over study design</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>visit 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.74"/>
                    <measurement group_id="O2" value="NA">cross over study design</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>visit 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.99"/>
                    <measurement group_id="O2" value="NA">cross over study design</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Levels of Serum LH</title>
        <description>Blood samples measured by Beckman assays and equipment.</description>
        <time_frame>&quot;Visit 2, Visit 3, Visit 4, Visit 5, Visit 6 and Visit 7&quot;</time_frame>
        <population>loss to follow up</population>
        <group_list>
          <group group_id="O1">
            <title>&quot;SQ&quot;</title>
            <description>Subcutaneous testosterone injection Testosterone: Testosterone cypionate injection</description>
          </group>
          <group group_id="O2">
            <title>&quot;IM&quot;</title>
            <description>Intramuscular testosterone injection Testosterone : Testosterone cypionate injection</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Levels of Serum LH</title>
          <description>Blood samples measured by Beckman assays and equipment.</description>
          <population>loss to follow up</population>
          <units>miu/ml</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>visit 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">cross over study design</measurement>
                    <measurement group_id="O2" value="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>visit 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">cross over study design</measurement>
                    <measurement group_id="O2" value="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>visit 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2"/>
                    <measurement group_id="O2" value="NA">cross over study design</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>visit 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04"/>
                    <measurement group_id="O2" value="NA">cross over study design</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>visit 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1"/>
                    <measurement group_id="O2" value="NA">cross over study design</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>visit 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4"/>
                    <measurement group_id="O2" value="NA">cross over study design</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Levels of Serum FSH</title>
        <description>Blood samples measured by Beckman assays and equipment.</description>
        <time_frame>&quot;Visit 2, Visit 3, Visit 4, Visit 5, Visit 6 and Visit 7&quot;</time_frame>
        <population>loss to follow up</population>
        <group_list>
          <group group_id="O1">
            <title>&quot;SQ&quot;</title>
            <description>Subcutaneous testosterone injection Testosterone: Testosterone cypionate injection</description>
          </group>
          <group group_id="O2">
            <title>&quot;IM&quot;</title>
            <description>Intramuscular testosterone injection Testosterone: Testosterone cypionate injection</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Levels of Serum FSH</title>
          <description>Blood samples measured by Beckman assays and equipment.</description>
          <population>loss to follow up</population>
          <units>miu/ml</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>visit 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">cross over study design</measurement>
                    <measurement group_id="O2" value="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>visit 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">cross over study design</measurement>
                    <measurement group_id="O2" value="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>visit 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2"/>
                    <measurement group_id="O2" value="NA">cross over study design</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>visit 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1"/>
                    <measurement group_id="O2" value="NA">cross over study design</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>visit 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05"/>
                    <measurement group_id="O2" value="NA">cross over study design</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>visit 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3"/>
                    <measurement group_id="O2" value="NA">cross over study design</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Levels of Serum SHBG</title>
        <description>Blood samples measured by Beckman assays and equipment.</description>
        <time_frame>&quot;Visit 2, Visit 3, Visit 4, Visit 5, Visit 6 and Visit 7&quot;</time_frame>
        <population>loss to follow up</population>
        <group_list>
          <group group_id="O1">
            <title>&quot;SQ&quot;</title>
            <description>Subcutaneous testosterone injection Testosterone: Testosterone cypionate injection</description>
          </group>
          <group group_id="O2">
            <title>&quot;IM&quot;</title>
            <description>Intramuscular testosterone injection Testosterone: Testosterone cypionate injection</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Levels of Serum SHBG</title>
          <description>Blood samples measured by Beckman assays and equipment.</description>
          <population>loss to follow up</population>
          <units>nmol/l</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>visit 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">cross over study design</measurement>
                    <measurement group_id="O2" value="25.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>visit 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">cross over study design</measurement>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>visit 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.8"/>
                    <measurement group_id="O2" value="NA">cross over study design</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>visit 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.8"/>
                    <measurement group_id="O2" value="NA">cross over study design</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>visit 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.9"/>
                    <measurement group_id="O2" value="NA">cross over study design</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>visit 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.7"/>
                    <measurement group_id="O2" value="NA">cross over study design</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Level of Serum PSA</title>
        <description>Blood samples measured by Beckman assays and equipment.</description>
        <time_frame>&quot;Last visit (Visit 7)&quot;</time_frame>
        <population>loss to follow up</population>
        <group_list>
          <group group_id="O1">
            <title>&quot;SQ&quot;</title>
            <description>Subcutaneous testosterone injection Testosterone: Testosterone cypionate injection</description>
          </group>
          <group group_id="O2">
            <title>&quot;IM&quot;</title>
            <description>Intramuscular testosterone injection Testosterone: Testosterone cypionate injection</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Level of Serum PSA</title>
          <description>Blood samples measured by Beckman assays and equipment.</description>
          <population>loss to follow up</population>
          <units>ng/mL</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25"/>
                    <measurement group_id="O2" value="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Levels of Whole Blood Hematocrit</title>
        <description>Blood samples measured by Quest assays and equipment.</description>
        <time_frame>&quot;Last visit (Visit 7)&quot;</time_frame>
        <population>loss to follow up</population>
        <group_list>
          <group group_id="O1">
            <title>&quot;SQ&quot;</title>
            <description>Subcutaneous testosterone injection Testosterone: Testosterone cypionate injection</description>
          </group>
          <group group_id="O2">
            <title>&quot;IM&quot;</title>
            <description>Intramuscular testosterone injection Testosterone: Testosterone cypionate injection</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Levels of Whole Blood Hematocrit</title>
          <description>Blood samples measured by Quest assays and equipment.</description>
          <population>loss to follow up</population>
          <units>g/dL</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">insufficient number of participants with event/measures.</measurement>
                    <measurement group_id="O2" value="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Low Testosterone Questionnaire Responses</title>
        <description>Answers recorded at baseline, 2 weeks, up to 4 weeks. Scale is 1-5 (strongly disagree to strongly agree) Lower scores are better</description>
        <time_frame>after last vist #7</time_frame>
        <population>loss to follow up</population>
        <group_list>
          <group group_id="O1">
            <title>&quot;SQ&quot;</title>
            <description>Subcutaneous testosterone injection Testosterone: Testosterone cypionate injection</description>
          </group>
          <group group_id="O2">
            <title>&quot;IM&quot;</title>
            <description>Intramuscular testosterone injection Testosterone: Testosterone cypionate injection</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Low Testosterone Questionnaire Responses</title>
          <description>Answers recorded at baseline, 2 weeks, up to 4 weeks. Scale is 1-5 (strongly disagree to strongly agree) Lower scores are better</description>
          <population>loss to follow up</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in International Prostate Symptom Scores</title>
        <description>Answers recorded at baseline, 2 weeks, up to 4 weeks.
Scale 0-35, from Mild to Severe Lower score is better</description>
        <time_frame>after last vist #7</time_frame>
        <population>loss to follow up</population>
        <group_list>
          <group group_id="O1">
            <title>&quot;SQ&quot;</title>
            <description>Subcutaneous testosterone injection Testosterone: Testosterone cypionate injection</description>
          </group>
          <group group_id="O2">
            <title>&quot;IM&quot;</title>
            <description>Intramuscular testosterone injection Testosterone: Testosterone cypionate injection</description>
          </group>
        </group_list>
        <measure>
          <title>Change in International Prostate Symptom Scores</title>
          <description>Answers recorded at baseline, 2 weeks, up to 4 weeks.
Scale 0-35, from Mild to Severe Lower score is better</description>
          <population>loss to follow up</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AE were monitored/assessed at each study visit.</time_frame>
      <desc>An adverse event is defined as any untoward or unfavorable medical occurrence in a human subject including any abnormal sign, symptom, or disease temporally associated with the subject's participation in the research, whether or not considered related to the subject's participation in the research. Include the type and duration of the follow‐up of subjects after adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>SQ Testosterone</title>
          <description>Subcutaneous testosterone injection Testosterone: Testosterone cypionate injection</description>
        </group>
        <group group_id="E2">
          <title>IM Testosterone</title>
          <description>Intramuscular testosterone injection Testosterone: Testosterone cypionate injection</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Abraham Morgentaler</name_or_title>
      <organization>Men</organization>
      <phone>617-277-5000</phone>
      <email>research@menshealthboston.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

